[JHVEPhoto - stock.adobe.com]

Healthcare & technology are my 2 top investment areas 

Not only because they often produce inventions, which have the potential to generate best-in-class returns, but also because they can make a real, sustainable difference to the world & millions of people’s lives everywhere - alongside being fascinating topics to research & understand.

Take LunglifeAI llai   , which is developing ground-breaking new diagnostics to identify & treat early-stage lung cancer – based on harvesting circulating tumour cells (CTCs) from a single blood draw. A disease which globally kills around 1.8m people each year – the vast majority of whom are diagnosed late, where survival rates are low.

In fact, by deploying LLAI’s patented, well balanced, AI enhanced & highly accurate LungLB test (89% PPV), doctors will instead hopefully be able to identify 80% of lung cancer cases sufficiently early to materially improve treatment regimes.
What’s more today, the firm said that after conducting a detailed on-site audit, New York State had approved LungLB for commercial testing – adding to its other 46 state authorisations.

This is important given LLAI’s close relationship with Mount Sinai (9.7% shareholder), a key site in the ongoing pivotal validation trial (ie to confirm the test’s clinical performance) and planned 2023 utility studies (ie to measure the test’s healthcare benefits for patients) from which 1st revenues are expected.

 

View from Vox

The multi-centre validation study involves an estimated 425 participants & should finish by Q1’23. After which the clinical data will be analysed, & appropriate regulatory approvals sought, along with US medical insurance cover.
 

Similarly unlocking a possible $2.9bn TAM in the US alone – assuming a hypothetical price of $950/test.

Lara Baden, VP of Clinical Operations commenting: "We are pleased to have received a CLEP permit from the NYSDOH. Not only does this provide further validation of our best-in-class quality system, but also approval of the LungLB test means that LungLife AI can offer this service to physicians in New York state who evaluate indeterminate lung nodules for early cancer detection."


Onwards & upwards!